<p>Ipswich Investment Management Co. Inc. 在第三季度将其在礼来的股份提高了 21.3%，根据其最近向证券交易委员会（SEC）提交的 13F 表格。该基金在季度内额外购买了 1,230 股后，持有该公司 6,995 股股票。礼来公司占 Ipswich Investment Management Co. Inc.持股的 1.2%，是其第 24 大持股。根据 Ipswich Investment Management Co. Inc.最近向证券交易委员会（SEC）提交的文件，其在礼来公司的持股价值为 5,337,000 美元。</p>
<ul>
<li>三家医疗巨头刚刚提高了股息——看看谁支付得最多</li>
</ul>
<p>其他几家机构投资者也增加或减少了在 LLY 的持股。先锋集团（Vanguard Group Inc.）在第二季度将其在礼来公司的股份提高了 1.5%。先锋集团目前持有 80,407,430 股该公司的股票，价值 62,680,004,000 美元，在上个季度又购买了 1,183,038 股。劳雷尔财富顾问（Laurel Wealth Advisors LLC）在第二季度将其在礼来公司的持股提高了 78,621.2%。劳雷尔财富顾问目前持有 11,552,336 股该公司的股票，价值 9,005,392,000 美元，在此期间又购买了 11,537,661 股。挪威银行（Norges Bank）在第二季度购买了价值 8,827,714,000 美元的礼来公司新股份。詹尼森协会（Jennison Associates LLC）在第二季度将其在礼来公司的持股提高了 4.3%。詹尼森协会目前持有 5,447,636 股该公司的股票，价值 4,246,596,000 美元，在此期间又购买了 226,620 股。最后，Alliancebernstein L.P.在第一季度将其在礼来公司的持股提高了 7.9%。Alliancebernstein L.P.目前持有 5,443,919 股该公司的股票，价值 4,496,187,000 美元，在此期间又购买了 397,696 股。目前 82.53% 的股票由机构投资者持有。</p>
<p>获取 <strong>礼来公司</strong> 的提醒：</p>
<h2>华尔街分析师的看法</h2>
<p>多家券商最近对 LLY 发布了报告。古根海姆（Guggenheim）在 12 月 3 日的研究报告中重申了对礼来公司的 “买入” 评级，并给出了 1,163.00 美元的目标价。国家银行（National Bankshares）在 12 月 1 日的研究报告中设定了礼来公司的 1,286.00 美元目标价。大和资本市场（Daiwa Capital Markets）在周二的研究报告中设定了礼来公司的 1,230.00 美元目标价，并给予该股票 “买入” 评级。摩根士丹利（Morgan Stanley）在 11 月 24 日的研究报告中将礼来公司的目标价从 1,171.00 美元提高到 1,290.00 美元，并给予公司 “增持” 评级。最后，美国银行（Bank of America）在 12 月 15 日的研究报告中将礼来公司的目标价从 1,286.00 美元下调至 1,268.00 美元，并对该股票设定了 “买入” 评级。四位分析师给予该股票 “强烈买入” 评级，十七位分析师给予 “买入” 评级，五位分析师给予 “持有” 评级。根据 MarketBeat 的数据，礼来公司的共识评级为 “适度买入”，平均目标价为 1,141.73 美元。</p>
<ul>
<li>辉瑞增加对减肥药的重大投资</li>
</ul>
<p><strong>查看我们最新的 LLY 股票报告</strong></p>
<h2>礼来公司的价格表现</h2>
<p>礼来公司（NYSE:LLY）周五开盘价为 1,071.35 美元。该公司的速动比率为 1.24，流动比率为 1.55，债务与股本比率为 1.71。礼来公司的 12 个月低点为 623.78 美元，12 个月高点为 1,111.99 美元。该股票的 50 日移动平均线为 960.76 美元，200 日移动平均线为 830.36 美元。该公司的市值为 1.01 万亿美元，市盈率为 52.41，PEG 比率为 1.33，贝塔值为 0.37。</p>
<ul>
<li>黄金交叉警报：3 只具有重大上涨潜力的股票</li>
</ul>
<p>礼来公司（NYSE:LLY - 获取免费报告）最近在 10 月 30 日发布了季度财报。该公司报告每股收益（EPS）为 7.02 美元，超出市场共识预期的 6.42 美元，超出 0.60 美元。该公司在本季度的收入为 176 亿美元，而市场共识预期为 160.9 亿美元。礼来公司的净利润率为 30.99%，股本回报率为 109.52%。与去年同期相比，礼来公司的收入增长了 53.9%。去年同期，该公司每股收益为 1.18 美元。礼来公司已将其 2025 财年的指导目标设定为 23.000-23.700 的每股收益。卖方分析师预测，礼来公司在当前财年将发布 23.48 的每股收益。</p>
<h2>礼来公司增加股息</h2>
<p>该公司最近还宣布了一项季度股息，将于 3 月 10 日（星期二）支付。记录在案的股东将在 2 月 13 日（星期五）获得每股 1.73 美元的股息。该股息的除息日期为 2 月 13 日（星期五）。这比礼来公司之前的季度股息 1.50 美元有所增加。这代表着每年 6.92 美元的股息和 0.6% 的股息收益率。礼来公司的派息比率目前为 29.35%。</p>
<h2>礼来公司新闻摘要</h2>
<p>以下是本周影响礼来公司的主要新闻故事：</p>
<ul>
<li>积极情绪：晚期试验胜利——礼来公司的口服 GLP-1 药物 orforglipron 在 ATTAIN-MAINTAIN 第三阶段试验中达到了主要和所有关键的次要终点，显示从 Wegovy 或 Zepbound 转换的患者几乎保持了所有之前的体重减轻；礼来已向 FDA 提交了 orforglipron 用于肥胖症的申请。PR Newswire：礼来的 orforglipron 帮助人们维持体重减轻</li>
<li>积极情绪：项目势头和监管进展——中外制药和其他发布强调了积极的第三阶段顶线结果以及礼来对 orforglipron 的 FDA 申请，强化了公司在口服 GLP-1 领域的领导地位。如果获得批准，这将提高快速商业化的前景。TipRanks：中外制药强调积极的第三阶段结果</li>
<li>积极情绪：分析师升级和上行预测——美国银行和其他机构指出改善的质量指标并预测实质性上行（美国银行提到新口服肥胖疗法可能带来数十亿美元的销售），同时大和证券升级了 LLY——所有这些都支持更高的估值。Benzinga：美国银行看到股票上行空间 American Banking News：大和证券升级</li>
<li>中性情绪：管道深度——礼来将 eloralintide 推进到第三阶段，增强了其在肥胖/糖尿病领域的管道，超越了 orforglipron；这对长期增长具有战略意义，但不是立即的收入驱动因素。TipRanks：礼来将 eloralintide 推进到第三阶段</li>
<li>中性情绪：品牌/营销举措——礼来的消费者推广（例如，奥运会合作）支持新疗法的认知，但对短期财务影响不明确。MM&amp;M：礼来推出了以美国队为主题的视频</li>
<li>消极情绪：加拿大的价格压力——路透社报道，礼来在加拿大将 Mounjaro 和 Zepbound 的价格削减了约 20% 或更多，这可能会压缩利润率或减少在面临更严格定价/监管审查的市场中每个处方的实际收入。路透社：礼来在加拿大降低糖尿病和减肥药物的价格</li>
</ul>
<h2>关于礼来公司</h2>
<p>(免费报告)</p>
<p>礼来公司（Eli Lilly and Company）纽约证券交易所代码：LLY，是一家成立于 1876 年的全球制药公司，总部位于印第安纳州印第安纳波利斯。该公司研究、开发、生产和商业化广泛的药物和疗法，服务于全球患者。礼来在北美、欧洲、亚洲和其他地区开展业务并拥有商业存在，服务于发达市场和新兴市场。近年来，公司由总裁兼首席执行官 David A.领导。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票超过礼来公司</li>
<li>投资者如何找到最佳的便宜股息股票</li>
<li>耐克盈利超预期但在中国面临困难并遭遇关税</li>
<li>3 只值得购买的医疗保健股息股票</li>
<li>人工智能热潮是泡沫吗？这两只股息股票说不是</li>
<li>动荡市场中的资产配置策略</li>
<li>2026 年四只高潜力 ETF：小型股、太空股票等</li>
</ul>
<p><strong>想看看其他对 LLY 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取礼来公司（NYSE:LLY - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
<p>在考虑礼来公司之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄推荐给客户的股票，以便在更广泛的市场注意到之前购买……而礼来公司并不在名单上。</p>
<p>虽然礼来公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

礼来

<p>Ipswich Investment Management Co. Inc. 在第三季度将其在礼来的股份增加了 21.3%，目前持有 6,995 股，价值 534 万美元。这使得礼来占 Ipswich 投资组合的 1.2%。其他机构投资者，如先锋集团和挪威银行，也调整了他们的持股。礼来的股票获得了一致的 “适度买入” 评级，平均目标价格为 1,141.73 美元。该公司报告了强劲的季度收益，收入同比增长 53.9%</p>

<p>Ipswich Investment Management Co. Inc. lifted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 21.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,995 shares of the company's stock after acquiring an additional 1,230 shares during the quarter. Eli Lilly and Company makes up 1.2% of Ipswich Investment Management Co. Inc.'s holdings, making the stock its 24th biggest holding. Ipswich Investment Management Co. Inc.'s holdings in Eli Lilly and Company were worth $5,337,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>Ipswich Investment Management Co. Inc. 在第三季度将其在礼来的股份提高了 21.3%，根据其最近向证券交易委员会（SEC）提交的 13F 表格。该基金在季度内额外购买了 1,230 股后，持有该公司 6,995 股股票。礼来公司占 Ipswich Investment Management Co. Inc.持股的 1.2%，是其第 24 大持股。根据 Ipswich Investment Management Co. Inc.最近向证券交易委员会（SEC）提交的文件，其在礼来公司的持股价值为 5,337,000 美元。</p>
</div><ul>
<li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li>
</ul>
<div class="lb-trans"><ul>
<li>三家医疗巨头刚刚提高了股息——看看谁支付得最多</li>
</ul>
</div><p>Several other institutional investors have also added to or reduced their stakes in LLY. Vanguard Group Inc. boosted its stake in shares of Eli Lilly and Company by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company's stock valued at $62,680,004,000 after purchasing an additional 1,183,038 shares during the last quarter. Laurel Wealth Advisors LLC lifted its holdings in Eli Lilly and Company by 78,621.2% in the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company's stock valued at $9,005,392,000 after buying an additional 11,537,661 shares during the period. Norges Bank bought a new stake in Eli Lilly and Company during the second quarter valued at $8,827,714,000. Jennison Associates LLC grew its holdings in Eli Lilly and Company by 4.3% during the 2nd quarter. Jennison Associates LLC now owns 5,447,636 shares of the company's stock worth $4,246,596,000 after acquiring an additional 226,620 shares during the period. Finally, Alliancebernstein L.P. grew its holdings in Eli Lilly and Company by 7.9% during the 1st quarter. Alliancebernstein L.P. now owns 5,443,919 shares of the company's stock worth $4,496,187,000 after acquiring an additional 397,696 shares during the period. 82.53% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他几家机构投资者也增加或减少了在 LLY 的持股。先锋集团（Vanguard Group Inc.）在第二季度将其在礼来公司的股份提高了 1.5%。先锋集团目前持有 80,407,430 股该公司的股票，价值 62,680,004,000 美元，在上个季度又购买了 1,183,038 股。劳雷尔财富顾问（Laurel Wealth Advisors LLC）在第二季度将其在礼来公司的持股提高了 78,621.2%。劳雷尔财富顾问目前持有 11,552,336 股该公司的股票，价值 9,005,392,000 美元，在此期间又购买了 11,537,661 股。挪威银行（Norges Bank）在第二季度购买了价值 8,827,714,000 美元的礼来公司新股份。詹尼森协会（Jennison Associates LLC）在第二季度将其在礼来公司的持股提高了 4.3%。詹尼森协会目前持有 5,447,636 股该公司的股票，价值 4,246,596,000 美元，在此期间又购买了 226,620 股。最后，Alliancebernstein L.P.在第一季度将其在礼来公司的持股提高了 7.9%。Alliancebernstein L.P.目前持有 5,443,919 股该公司的股票，价值 4,496,187,000 美元，在此期间又购买了 397,696 股。目前 82.53% 的股票由机构投资者持有。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>礼来公司</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师的看法</h2>
</div><p>A number of brokerages have recently issued reports on LLY. Guggenheim reissued a &#34;buy&#34; rating and issued a $1,163.00 price objective on shares of Eli Lilly and Company in a research note on Wednesday, December 3rd. National Bankshares set a $1,286.00 price target on Eli Lilly and Company in a research note on Monday, December 1st. Daiwa Capital Markets set a $1,230.00 price objective on shares of Eli Lilly and Company and gave the stock a &#34;buy&#34; rating in a research report on Tuesday. Morgan Stanley lifted their price objective on shares of Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the company an &#34;overweight&#34; rating in a research note on Monday, November 24th. Finally, Bank of America dropped their target price on shares of Eli Lilly and Company from $1,286.00 to $1,268.00 and set a &#34;buy&#34; rating on the stock in a research report on Monday, December 15th. Four analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, Eli Lilly and Company has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $1,141.73.</p>
<div class="lb-trans"><p>多家券商最近对 LLY 发布了报告。古根海姆（Guggenheim）在 12 月 3 日的研究报告中重申了对礼来公司的 “买入” 评级，并给出了 1,163.00 美元的目标价。国家银行（National Bankshares）在 12 月 1 日的研究报告中设定了礼来公司的 1,286.00 美元目标价。大和资本市场（Daiwa Capital Markets）在周二的研究报告中设定了礼来公司的 1,230.00 美元目标价，并给予该股票 “买入” 评级。摩根士丹利（Morgan Stanley）在 11 月 24 日的研究报告中将礼来公司的目标价从 1,171.00 美元提高到 1,290.00 美元，并给予公司 “增持” 评级。最后，美国银行（Bank of America）在 12 月 15 日的研究报告中将礼来公司的目标价从 1,286.00 美元下调至 1,268.00 美元，并对该股票设定了 “买入” 评级。四位分析师给予该股票 “强烈买入” 评级，十七位分析师给予 “买入” 评级，五位分析师给予 “持有” 评级。根据 MarketBeat 的数据，礼来公司的共识评级为 “适度买入”，平均目标价为 1,141.73 美元。</p>
</div><ul>
<li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>辉瑞增加对减肥药的重大投资</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Report on LLY</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 LLY 股票报告</strong></p>
</div><h2>Eli Lilly and Company Price Performance</h2>
<div class="lb-trans"><h2>礼来公司的价格表现</h2>
</div><p>Shares of NYSE:LLY opened at $1,071.35 on Friday. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,111.99. The stock's 50 day moving average is $960.76 and its 200-day moving average is $830.36. The firm has a market capitalization of $1.01 trillion, a price-to-earnings ratio of 52.41, a PEG ratio of 1.33 and a beta of 0.37.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY）周五开盘价为 1,071.35 美元。该公司的速动比率为 1.24，流动比率为 1.55，债务与股本比率为 1.71。礼来公司的 12 个月低点为 623.78 美元，12 个月高点为 1,111.99 美元。该股票的 50 日移动平均线为 960.76 美元，200 日移动平均线为 830.36 美元。该公司的市值为 1.01 万亿美元，市盈率为 52.41，PEG 比率为 1.33，贝塔值为 0.37。</p>
</div><ul>
<li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>黄金交叉警报：3 只具有重大上涨潜力的股票</li>
</ul>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. Eli Lilly and Company's revenue was up 53.9% compared to the same quarter last year. During the same quarter last year, the firm posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）最近在 10 月 30 日发布了季度财报。该公司报告每股收益（EPS）为 7.02 美元，超出市场共识预期的 6.42 美元，超出 0.60 美元。该公司在本季度的收入为 176 亿美元，而市场共识预期为 160.9 亿美元。礼来公司的净利润率为 30.99%，股本回报率为 109.52%。与去年同期相比，礼来公司的收入增长了 53.9%。去年同期，该公司每股收益为 1.18 美元。礼来公司已将其 2025 财年的指导目标设定为 23.000-23.700 的每股收益。卖方分析师预测，礼来公司在当前财年将发布 23.48 的每股收益。</p>
</div><h2>Eli Lilly and Company Increases Dividend</h2>
<div class="lb-trans"><h2>礼来公司增加股息</h2>
</div><p>The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This is a boost from Eli Lilly and Company's previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company's payout ratio is presently 29.35%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度股息，将于 3 月 10 日（星期二）支付。记录在案的股东将在 2 月 13 日（星期五）获得每股 1.73 美元的股息。该股息的除息日期为 2 月 13 日（星期五）。这比礼来公司之前的季度股息 1.50 美元有所增加。这代表着每年 6.92 美元的股息和 0.6% 的股息收益率。礼来公司的派息比率目前为 29.35%。</p>
</div><h2>Eli Lilly and Company News Summary</h2>
<div class="lb-trans"><h2>礼来公司新闻摘要</h2>
</div><p>Here are the key news stories impacting Eli Lilly and Company this week:</p>
<div class="lb-trans"><p>以下是本周影响礼来公司的主要新闻故事：</p>
</div><ul>
<li>Positive Sentiment: Late‑stage trial win — Lilly’s oral GLP‑1 pill orforglipron met the primary and all key secondary endpoints in the ATTAIN‑MAINTAIN Phase 3 trial, showing patients who switched from Wegovy or Zepbound kept essentially all prior weight loss; Lilly has submitted orforglipron to the FDA for obesity. PR Newswire: Lilly's orforglipron helped people maintain weight loss</li>
<li>Positive Sentiment: Program momentum and regulatory progress — Chugai and other releases highlight positive topline Phase 3 results and Lilly’s FDA filing for orforglipron, reinforcing the company’s leadership in oral GLP‑1s. This raises prospects for rapid commercial adoption if approved. TipRanks: Chugai highlights positive Phase 3 results</li>
<li>Positive Sentiment: Analyst upgrades and upside forecasts — Bank of America and other outlets point to improved quality metrics and forecast material upside (BofA cites potential multi‑billion sales for new oral obesity therapies), while Daiwa upgraded LLY — all supportive of higher valuations. Benzinga: BofA sees room for stock upsideAmerican Banking News: Daiwa upgrade</li>
<li>Neutral Sentiment: Pipeline depth — Lilly advanced eloralintide into Phase 3, strengthening its obesity/diabetes pipeline beyond orforglipron; this is strategic for longer‑term growth but not an immediate revenue driver. TipRanks: Lilly advances eloralintide into Phase 3</li>
<li>Neutral Sentiment: Branding/marketing initiatives — Lilly’s consumer outreach (e.g., Olympics tie‑ins) supports awareness for new therapies but has unclear near‑term financial impact. MM&amp;M: Lilly debuts video featuring Team USA</li>
<li>Negative Sentiment: Pricing pressure in Canada — Reuters reported Lilly cut prices of Mounjaro and Zepbound in Canada by ~20% or more, which could compress margins or reduce realized revenue per prescription in markets facing tougher pricing/regulatory scrutiny. Reuters: Lilly cuts price of diabetes, weight-loss drugs in Canada</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：晚期试验胜利——礼来公司的口服 GLP-1 药物 orforglipron 在 ATTAIN-MAINTAIN 第三阶段试验中达到了主要和所有关键的次要终点，显示从 Wegovy 或 Zepbound 转换的患者几乎保持了所有之前的体重减轻；礼来已向 FDA 提交了 orforglipron 用于肥胖症的申请。PR Newswire：礼来的 orforglipron 帮助人们维持体重减轻</li>
<li>积极情绪：项目势头和监管进展——中外制药和其他发布强调了积极的第三阶段顶线结果以及礼来对 orforglipron 的 FDA 申请，强化了公司在口服 GLP-1 领域的领导地位。如果获得批准，这将提高快速商业化的前景。TipRanks：中外制药强调积极的第三阶段结果</li>
<li>积极情绪：分析师升级和上行预测——美国银行和其他机构指出改善的质量指标并预测实质性上行（美国银行提到新口服肥胖疗法可能带来数十亿美元的销售），同时大和证券升级了 LLY——所有这些都支持更高的估值。Benzinga：美国银行看到股票上行空间 American Banking News：大和证券升级</li>
<li>中性情绪：管道深度——礼来将 eloralintide 推进到第三阶段，增强了其在肥胖/糖尿病领域的管道，超越了 orforglipron；这对长期增长具有战略意义，但不是立即的收入驱动因素。TipRanks：礼来将 eloralintide 推进到第三阶段</li>
<li>中性情绪：品牌/营销举措——礼来的消费者推广（例如，奥运会合作）支持新疗法的认知，但对短期财务影响不明确。MM&amp;M：礼来推出了以美国队为主题的视频</li>
<li>消极情绪：加拿大的价格压力——路透社报道，礼来在加拿大将 Mounjaro 和 Zepbound 的价格削减了约 20% 或更多，这可能会压缩利润率或减少在面临更严格定价/监管审查的市场中每个处方的实际收入。路透社：礼来在加拿大降低糖尿病和减肥药物的价格</li>
</ul>
</div><h2>About Eli Lilly and Company</h2>
<div class="lb-trans"><h2>关于礼来公司</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.</p>
<div class="lb-trans"><p>礼来公司（Eli Lilly and Company）纽约证券交易所代码：LLY，是一家成立于 1876 年的全球制药公司，总部位于印第安纳州印第安纳波利斯。该公司研究、开发、生产和商业化广泛的药物和疗法，服务于全球患者。礼来在北美、欧洲、亚洲和其他地区开展业务并拥有商业存在，服务于发达市场和新兴市场。近年来，公司由总裁兼首席执行官 David A.领导。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>How Investors Can Find the Best Cheap Dividend Stocks</li>
<li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li>
<li>3 Healthcare Dividend Stocks to Buy</li>
<li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li>
<li>Asset Allocation Strategies in Volatile Markets</li>
<li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过礼来公司</li>
<li>投资者如何找到最佳的便宜股息股票</li>
<li>耐克盈利超预期但在中国面临困难并遭遇关税</li>
<li>3 只值得购买的医疗保健股息股票</li>
<li>人工智能热潮是泡沫吗？这两只股息股票说不是</li>
<li>动荡市场中的资产配置策略</li>
<li>2026 年四只高潜力 ETF：小型股、太空股票等</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding LLY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 LLY 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取礼来公司（NYSE:LLY - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑礼来公司之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄推荐给客户的股票，以便在更广泛的市场注意到之前购买……而礼来公司并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然礼来公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Ipswich Investment Management Co. Inc. 持有价值 534 万美元的礼来公司股票